Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP7 | P09237 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 7/20 | 0.45 |
| ▸ | GUSB | P08236 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | EBP | Q15125 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2888598 | 0.83 | MMP3 (0.46) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL2886117 | 0.78 | MMP1 (0.62) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL2890129 | 0.76 | MMP1 (0.62) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL7540507 | 0.75 | BCHE (0.46) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL2882601 | 0.74 | MMP1 (0.50) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL2887777 | 0.74 | MMP1 (0.50) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL2888684 | 0.74 | MMP1 (0.50) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL1380196 | 0.74 | MMP1 (0.50) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL2887864 | 0.72 | MMP1 (0.48) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL19134546 | 0.69 | S1PR1 (0.56) | BCHEGUSBEBPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946227-B2 | Piperazine derivatives and methods of use | MERCK SERONO SA (CH) | 2015-02-03 | — | — | US | claimed |
| US-20130143893-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | MERCK SERONO SA (CH) | 2013-06-06 | — | — | US | claimed |
| EP-1542993-B1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | MERCK SERONO SA (CH) | 2012-12-19 | — | — | EP | claimed |
| JP-4713152-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| US-20100305137-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | claimed |
| US-7754722-B2 | Piperazine derivatives and methods of use | MERCK SERONO SA (CH) | 2010-07-13 | — | — | US | claimed |
| US-20060223813-A1 | Piperazine Derivatives and Methods of Use | MERCK SERONO SA (CH) | 2006-10-05 | — | — | US | claimed |
| EP-1542993-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | Applied Research Systems ARS Holding N.V. (AN) | 2005-06-22 | — | — | EP | claimed |
| WO-2004031182-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-04-15 | — | — | WO | claimed |
| US-8946227-B2 | Piperazine derivatives and methods of use | MERCK SERONO SA (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20130143893-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | MERCK SERONO SA (CH) | 2013-06-06 | — | — | US | disclosed |
| US-20100305137-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| US-7754722-B2 | Piperazine derivatives and methods of use | MERCK SERONO SA (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20060223813-A1 | Piperazine Derivatives and Methods of Use | MERCK SERONO SA (CH) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305137-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | CATSPER1, NASP, HDAC5 | MMP1 1946/4885MMP3 2049/4885MMP7 2485/4885 |
| US-20130143893-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | CATSPER1, NASP, HDAC5 | MMP1 1946/4885MMP3 2049/4885MMP7 2485/4885 |
| US-20060223813-A1 | Piperazine Derivatives and Methods of Use | CATSPER1, H1-5, GNRHR | MMP1 2763/4885MMP3 3308/4885MMP7 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.